Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
the patents used to be a concern of mine but my last 2 conversations with IR alleviated it. instead of everyone guessing......call them
Lake please read post 78438
thought it worth the time for EVERYONE to read this again.
Although 99% of the conversation and excitement on this board centers on ALZ, your 3a-3b and 3c are the near term keys to the MC of this company. They have acknowledged that the trial will start in 2017 ( 1st or 2nd quarter at the latest is a good guess)and that it will be of a SHORT duration. This trial can open the floodgates for AVXL.
ALZ is the big enchilada but RETTs is the near term key. A successful trial will mean BIG $$$$ soon which obviously increases their leverage
with BP.
jmho
Was going to echo your response . He doesn't understand awarded stock options
In addition to sending the article, I would ABSOLUTELY send the video as an attachment.
I believe they have been waiting for the most recent ( Saturday )data before starting partnership talks as it improved their bargaining position immensely.
jmho
they just had 175k on the ask from 2 different MMs at 3.73 and !poof! they were gone. This is gonna move HIGHER VERY soon
Eli Lilly's drug FAILS and they're bailing. Whats Anavex worth now ?
Whens the last time we closed at the HOD
What drew me to Anavex was that it seems to be the FIRST group to actually get closer to root cause for CNS diseases. I believe the PPS fluctuations/stagnations are VERY temporary.
jmho
Great view of whats transpiring
Somebody just bought >100k shares at 2.93 at the open
Have been gone. Whats the hullabaloo about the TA ? Also, does 2.70 look like the bottom to anyone else?
TIA
My science friend and I, ( who both have family with ADS), are encouraged by the MANY attempts and $$ being spent on ADS. It just seems that several companies are still after the fact. AVXL seems to be the leader in root cause analysis with a potential for STOPPiNG protein misfolding.
I think your waiting for a AD phase 3 trial and believe its the next significant milestone is short sighted. If (when) Biogen moves to the mouse model AND the start of a Rhetts syndrome phase 2 are going to be HUGE.
jmho
Does anyone know if AVXL will have a presence at the conference?
I actually believe that by doing this they are defining and validating there data definitively for 2 reasons:
To solidify their planned phase 3 working with the FDA AND TO BOLSTER THEIR LEVERAGE IN GETTING MORE FROM A PARTNER.
I just don't see how they could possibly be thinking about going it alone,
If you want to know PK/PD data you should contact Biogen as Im sure they have seen it and are thus going forward with A2-73
Listening now........why isn't the market capitalization for Anavex $1Billion right now? As I follow many small biotechs.... I must be missing something here...
Quit reading the message boards . Evaluate the science, and if you can't , pay some one. GOLD MINE here
Isn't there a presentation by Missling on Tuesday where it would seem appropriate to give updated AD data.
or it may not be used at all.
I'm long IGXT BUT you must consider the 6M warrants priced at $.56. Nice profit for them at these levels
I'm personally confused. You are on the AVXL board, do you like their prospects ?
My take is that AD may actually be on the back burner and that their attention has shifted to RHETTS and Parkinsons. Both trials would certainly be HUGELY shorter than the eventual AD trial
I'm all for effectuating the S3 and bringing in approximately $9m. This is very minor dilution and gives them a runway well into next year.
jmho
whats everyone freaking out about ? They can get $22M by issuing 6m at $3.36. And yes LPC will sell shares at $4 and up for a while(approx 8 business days worth of trading ). MOST IMPORTANTLY rhett syndrome trial funded.
I have personally put ALZ out to next year. Thats when we need to partner.
If rhetts is successful, we'll have a Billion $ market cap.
This is a positive
Looks like $$$ for the Rhetts syndrome trial. Like it
Looks like one more test of $3.30 might be in order and then I would guess we never have to deal with this ridiculous market cap.
Not a big science guy but 2 of my partners are. The trial results in their eyes are pretty much in line with their expectations. They are of the notion that oncs is absoluteyl on the right path and that they should command a market capitalization much higher than 130 m. I think I'll listen to them.
Old news. Was posted a long time ago. Still relevant.
Thinking 300-400M. Market Capitalization over next 1-3 months
Down goes Frazier
You are correct. I've attended many and this ongoing debate is ridiculous to me.
What I will share with you is that in private I guarantee that Punit is constantly being told that they won't or can't invest in OTC stocks. Punit is being told that they'll revisit ONCS once this has uplisted. Although getting the share price up organically is optimal, if after the upcoming catalysts are publicized and we are still lingering below a $1, he can't do a reverse split fast enough.
When reverse splits are enacted to maintain a listing, its bad news since there is most likely something inherently wrong with the company. On the other hand, if it is done to achieve transfer to a greater exchange it generally is very well received. In addition it would knock the snot out of the short positions.
I think you mean the ask not the bid
Predicting move up to .55 by Friday and then we finally start to see news next week.
if they're under 10% of the outstanding share count, they don't have to file disclosure with the SEC
let me think......INO's market capitalization is 4 times oncs's ( I know you don't even know what that is or the comparative analysis factor ). Stock price has NOTHING to do with the value of the company except for id*ots.
If the phase 2b combo trial is approved by the fda, big jump in appreciation coming.
If the implied catalysts occur, I think your market capitalization targets might actually be low based on what other companies have seen at this point in their development. I could actually see $300m-$400m before year's end.